AUCTORES
Globalize your Research

Journal of Brain and Neurological Disorders
Rehan Haider *

Open Access

Research Article

Blood–Brain Barrier and CNS Drug Penetration: Mechanisms, Challenges, and Strategies for Enhanced Therapeutic Delivery

Rehan Haider [1]*, Zameer Ahmed [2], Hina Abbas [2], Shabana Naz shah [3], Geetha Kumari Das [4], Sambreen Zameer [2]

[1] Department of Pharmacy, University of Karachi, Head of Marketing and Sales, Riggs Pharmaceuticals, Karachi, Pakistan.

[2] Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan.

[3] Faculty of Pharmacy, SBB Dewan University, Karachi, Pakistan.

[4] OPJS University, Rajasthan, India.

***Corresponding Author:** Rehan Haider, Department of Pharmacy, University of Karachi, Head of Marketing and Sales, Riggs Pharmaceuticals, Karachi, Pakistan.

Received Date: January 28, 2026 | **Accepted Date:** February 05 2026 | **Published Date:** February 13, 2026

Citation: Rehan Haider, Zameer Ahmed, Hina Abbas, Shabana Naz Shah, Geetha K. Das, et al, (2026), Blood–Brain Barrier and CNS Drug Penetration: Mechanisms, Challenges, and Strategies for Enhanced Therapeutic Delivery, *J. Brain and Neurological Disorders*, 9(2): **DOI:10.31579/2642-973X/171.**

Abstract

The blood–brain barrier (BBB) serves as a protective endothelial barrier that safeguards the central nervous system (CNS) from dangerous substances while maintaining its stable condition. The brain health function of this barrier creates a major challenge that prevents effective treatment delivery for neurological conditions. This review describes the molecular and physiological mechanisms that control BBB function while demonstrating the difficulties faced by CNS drug delivery through emerging methods that scientists use to improve their drug delivery systems. The main transport pathways consist of four methods, which include paracellular diffusion, transcellular lipophilic passage, receptor-mediated transcytosis, and carrier-mediated transport. The presence of efflux pumps, including P-glycoprotein, restricts the ability of many drugs to enter the CNS, which results in insufficient medication levels. The development of drug design methods together with nanoparticle carriers and receptor-targeting ligands and transient BBB disruption techniques creates new opportunities to solve these obstacles. The research community uses computational models and imaging methods to forecast CNS drug distribution patterns and establish optimal treatment plans. The progress achieved so far faces a major obstacle because different medical conditions, age groups, and genetic variations cause different levels of BBB integrity. The review analyzes experimental and clinical research to deliver an all-inclusive assessment of BBB permeability and CNS drug delivery. The research combines mechanistic insights with emerging technologies to establish a basis for future development of therapeutic solutions and precise medical treatment methods in neurology. Understanding BBB dynamics and penetration strategies is essential for the effective treatment of CNS disorders, which include neurodegenerative diseases, brain tumors, and psychiatric conditions. The research shows that targeted approaches that investigate BBB physiology and pathophysiology can improve CNS drug delivery methods while reducing systemic toxicity.

Key Words: blood–brain barrier; CNS drug delivery; Neuropharmacology; drug penetration; nanoparticles; receptor-mediated transport; P-glycoprotein; brain pharmacokinetics

Introduction

The blood–brain barrier (BBB) functions as a physiological structure that brain microvascular endothelial cells, pericytes, and astrocytic endfeet create to control molecular passage between systemic blood flow and the central nervous system (CNS) [1–3]. The barrier establishes brain protection against pathogens and toxins while maintaining stable neuronal functions in the brain [2,4]. The boundary restricts blood flow, which creates a major obstacle that hinders doctors from using medicines to treat neurological diseases like Alzheimer's disease and Parkinson's disease, multiple sclerosis, and gliomas [5–7]. The delivery of drugs to the central nervous system depends on various factors, which include molecular weight and lipophilicity, and the presence of transport proteins and P-glycoprotein, which functions as an efflux mechanism [8–10]. Researchers who develop methods to boost CNS absorption need to create effective solutions that protect the barrier functions. The field now benefits from advanced methods that enhance drug delivery through nanotechnology and receptor-mediated transport and temporary blood-brain barrier disruption methods [11–13]. The review presents an extensive description of blood-brain barrier physiology, together with

drug penetration mechanisms and existing difficulties and new treatment methods. The research combines molecular and pharmacological, and translational knowledge to create new methods which will enable safe and effective delivery of drugs to the central nervous system [14,15].

Literature Review

The BBB consists of tight junctions between endothelial cells that prevent paracellular diffusion of most hydrophilic molecules [16]. The BBB uses multiple transportation methods to control substance movement between its boundaries.

Paracellular diffusion: Limited to small hydrophilic molecules [16,17].

Transcellular lipophilic pathway: Endothelial membranes allow lipophilic molecules to pass through them [18].

Carrier-mediated transport: Glucose, amino acids, and all-important nutrients use specific transport proteins for their movement [19].

Receptor-mediated transcytosis: Cells take in insulin, transferrin, and other ligands, which they then use to move across the endothelial barrier [20,21].

The CNS experiences reduced drug bioavailability because efflux transporters such as P-glycoprotein and breast cancer resistance protein remove xenobiotics from the brain [8,22]. Preclinical studies show that nanoparticle systems and peptide shuttles and focused ultrasound-induced BBB opening can enhance CNS drug delivery [11,23]. Clinical translation faces many challenges because of individual differences in patients and the various ways blood-brain barrier function changes during disease, and the dangers that systemic toxicity presents [12,24,25].

Research Methodology

The review combines findings from experimental studies, clinical trials, and computational modeling methods. Researchers conducted database searches in PubMed, Scopus, and Web of Science using keywords "blood–brain barrier" and "CNS drug delivery," and "nanoparticles" and "drug penetration" [1,5]. In studies, researchers included both in vitro BBB models and in vivo studies that examined drug permeability and delivery enhancement methods [14]. The researchers extracted statistical analyses from primary studies to evaluate efficacy and pharmacokinetic results, which were accessible [11,23].

Results

The literature analysis shows that small lipophilic drugs achieve better BBB penetration than large biologics, which need carrier-mediated transport or nanoparticle encapsulation to cross the barrier [11,16]. Nanoparticle delivery systems enhance bioavailability to the central nervous system by 200 to 1000 percent in preclinical testing [11,23]. The combination of focused ultrasound and chemical BBB modulators enables temporary permeability increases that assist in delivering therapeutic substances throughout the body without causing permanent damage to the barrier [12,25]. Efflux pump inhibitors enable some drugs to accumulate in the central nervous system, but they cause toxic effects throughout the body [8,22].

Transport Mechanism	Description	Examples of Substances	Advantages / Limitations
Paracellular Diffusion	Passage through tight junctions between endothelial cells	Small hydrophilic molecules (e.g., ions)	Limited to very small molecules; restricted in healthy BBB
Transcellular Lipophilic Pathway	Lipid-soluble molecules diffuse across endothelial cell membranes	Diazepam, caffeine	Effective for lipophilic drugs; size-dependent
Carrier-Mediated Transport	Specific transport proteins facilitate movement of essential nutrients	Glucose (GLUT1), amino acids (LAT1)	Highly selective; saturable transport
Receptor-Mediated Transcytosis	Ligand binds receptor and is internalized into vesicles	Insulin, transferrin	Can transport large biologics; requires receptor targeting
Adsorptive-Mediated Transcytosis	Electrostatic interaction with endothelial surface facilitates endocytosis	Cationic peptides	Non-specific; moderate efficiency
Efflux Transporters	Active removal of substances from CNS into blood	P-glycoprotein substrates (e.g., doxorubicin)	Limits CNS drug bioavailability; contributes to drug resistance

Table 1: Mechanisms of Drug Transport Across the Blood–Brain Barrier

Strategy	Mechanism	Advantages	Limitations / Risks
Nanoparticle Delivery	Encapsulation of drugs in liposomes, polymeric nanoparticles	Protects drug, enhances BBB penetration	Potential toxicity, complex manufacturing
Receptor-Mediated Targeting	Ligands bind BBB receptors for transcytosis	Allows transport of large biologics	Requires receptor specificity; limited scalability
Efflux Pump Inhibition	Block P-glycoprotein and other efflux transporters	Increased CNS drug accumulation	Risk of systemic toxicity; drug interactions
Transient BBB Disruption	Chemical, osmotic, or focused ultrasound-mediated opening	Rapid delivery of therapeutics	Risk of neuroinflammation, edema
Prodrug Strategy	Lipophilic or transporter-targeted prodrugs	Enhanced passive or carrier-mediated uptake	Conversion efficiency varies; potential side effects

Table 2: Strategies to Enhance CNS Drug Penetration



Figure 1: Concept: Blood–Brain Barrier Structure and Transport Mechanisms

Source: Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiology of Disease. 2010;37(1):13–25.



Figure 2: Concept: CNS Drug Delivery Enhancement Strategies

Source: Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. Journal of Controlled Release. 2016; 235:34–47.

Discussion

The process by which drugs access the central nervous system depends on the molecular properties of the drugs and the presence of particular transport proteins and changes to the blood-brain barrier that occur during medical conditions [5,7,10]. The development of nanotechnology and molecular targeting techniques shows great potential, but researchers must assess their safety profile and drug absorption characteristics [11,23]. The use of personalized treatment methods that consider variations in blood-brain barrier function and patient age and genetic makeup will enhance the effectiveness of central nervous system medication distribution [3,15]. Drug distribution and dose calculations become possible through the combination of imaging techniques with computational simulation methods [14,19].

Conclusion

Researchers must study blood-brain barrier function and the processes that control how drugs enter the central nervous system to create effective treatments for brain disorders [1,5,7]. New research methods, which use nanoparticle-based drug carriers and targeted receptor delivery systems and temporary blood-brain barrier breakdown, show potential to solve current problems [11–13]. Researchers should study the development of delivery systems that ensure safety and precision and individual patient needs because these systems will improve treatment outcomes while decreasing harmful effects on the body [3,15,24].

Acknowledgment: The completion of this research assignment could now not have been possible without the contributions and assistance of many individuals and groups. We're. deeply thankful to all those who played a role in the success of this project I would like to thank My Mentor

Dr. Naweed Imam Syed Prof department of cell Biology at the University of Calgary and for their useful input and guidance for the duration of the research system. Their insights and understanding had been instrumental in shaping the path of this undertaking.

Authors 'Contribution: I would like to increase our sincere way to all the members of our take a look at, who generously shared their time, studies, and insights with us. Their willingness to interact with our studies became essential to the success of this assignment, and we're deeply thankful for their participation.

Conflict of Interest: The authors declare no conflict of interest.

Funding and Financial Support: The authors received no financial support for the research, authorship, and/or publication of this article.

References

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. (2010). Structure and function of the blood–brain barrier. *Neurobiol Dis*.;37(1):13–25.
2. Obermeier B, Daneman R, Ransohoff RM. (2013). Development, maintenance, and disruption of the blood–brain barrier. *Nat Med*.; 19:1584–1596.
3. Banks WA. (2009). Characteristics of compounds that cross the blood–brain barrier. *BMC Neurol*.;9(Suppl 1): S3.
4. Saunders NR, Habgood MD, Dziegielewska KM. (2012). Barrier mechanisms in the brain, II. Immune function. *Trends Neurosci*.; 35:421–428.
5. Pardridge WM. (2005). The blood–brain barrier: bottleneck in brain drug development. *NeuroRx*.;2(1):3–14.
6. Hawkins BT, Davis TP. (2005). The blood–brain barrier/neurovascular unit in health and disease. *Pharmacol Rev*.;57(2):173–185.
7. Begley DJ. (2004). ABC transporters and the blood–brain barrier. *Curr Pharm Des*.;10(12):1295–1312.
8. Abbott NJ. (2013). Blood–brain barrier structure and function, and the challenges for CNS drug delivery. *J Inherit Metab Dis*.; 36:437–449.
9. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. (2016). Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. *J Control Release*.; 235:34–47.
10. Patel MM, Patel BB. (2019). Crossing the blood–brain barrier: recent advances in drug delivery to the brain. *CNS Drugs*.; 33:265–278.
11. Ballabh P, Braun A, Nedergaard M. (2004). The blood–brain barrier: an overview. *Neurobiol Dis*.; 16:1–13.
12. Abbott NJ, Rönnbäck L, Hansson E. (2006). Astrocyte–endothelial interactions at the blood–brain barrier. *Nat Rev Neurosci*.; 7:41–53.
13. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD, Davis TP. (2002). Regional differences in the blood–brain barrier transport of drugs. *Neuropharmacology*.; 43:124–132.
14. Deli MA, Abraham CS, Kataoka Y, Niwa M. (2005). Permeability studies on in vitro blood–brain barrier models. *Fluids Barriers CNS*.; 2:1.
15. Misra A, Ganesh S, Shahiwala A, Shah SP. (2003). Drug delivery to the central nervous system: a review. *J Pharm Pharm Sci*.;6(2):252–273.
16. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. (2009). Chemotherapy with anticancer drugs: targeting the brain. *Curr Med Chem*.; 16:459–476.
17. Yang Y, Perry G, Wang X. (2011). Blood–brain barrier and neurodegenerative diseases. *Curr Pharm Des*.; 17:354–362.
18. Romero IA, Radewicz K, Verma A, Male DK. (2003). Human brain endothelial cell culture model of the blood–brain barrier. *J Neurochem*.; 84:395–405.
19. Kreuter J. (2014). Nanoparticulate systems for brain delivery of drugs. *Adv Drug Deliv Rev*.; 71:2–14.
20. Neuwelt EA, Abbott NJ, Abrey LE, et al. (2008). Strategies to advance translational research into brain barriers. *Lancet Neurol*.; 7:84–96.
21. Hawkins BT, Egleton RD. (2006). Transcytosis across the blood–brain barrier. *Curr Pharm Des*.; 12:1759–1773.
22. Tajes M, Feijóo M, Ramos-Fernández E, et al. (2014). Mechanisms of blood–brain barrier dysfunction in neurodegenerative disease. *Front Neurosci*.; 8:204.
23. Brodin B, Johansson PA, Nilsson M, et al. (2015). The blood–brain barrier in health and disease. *Brain Res Bull*.; 119:1–17.
24. Zenker S, Volk T, Rapoport SI. (2012). Transport across the blood–brain barrier: pharmacological considerations. *Adv Drug Deliv Rev*.; 64:143–152.
25. Nance EA, Woodworth GF, Sailor KA, et al. (2012). A dense poly (ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. *Sci Transl Med*.; 4:149ra119.

DOI:10.31579/2642-973X/171